louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05772065: Clinical Practice Guidelines Versus Decision-support for Latent Tuberculosis Infection (LTBI) Management
Official title: Evaluation of Clinical Practice Guidelines and Educational Decision-support Tools on Medical Trainees' Confidence With Latent Tuberculosis (LTBI) Testing and Treatment: A Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Latent Tuberculosis
Keywords: Tuberculosis
Education
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2023-03-16
Enrollment: 168
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Latent Tuberculosis infection (LTBI) guidelines can be complex. LTBI-ASSIST is a web-based interactive tool to navigate US LTBI clinical practice guidelines in a patient-centered format that may guide clinical decision making around Latent TB care.

The research goal is to determine the difference in reported confidence among trainees that are not experts in LTBI care. The investigators further aim to assess if access to the LTBI-ASSIST tool improves clinical decision making in a series of simulated case scenarios containing guideline-derived, multiple choice items, as well as assess the efficiency in navigating the scenarios - measured by time to complete the survey.

The investigators proposed a randomized study design, in which an electronic survey/questionnaire with 4 case scenarios consisting of 14 multiple choice questions. Participants providing informed consent will be randomized to receiving access to either US Centers for Disease Control (CDC)/National Tuberculosis (TB) Controllers Association (NTCA) Guidelines or the LTBI-ASSIST online tool. Those in the experimental arm will further complete a 10 question System Usability Scale to assess usability of the LTBI-ASSIST tool.

All Johns Hopkins medical trainees and residents will be eligible to participate.


Eligibility criteria: Inclusion Criteria:

* Student at Johns Hopkins School of Medicine, or Medical trainee at Hopkins Hospital or Bayview Program

Exclusion Criteria:

* None

Primary outcomes:
measure: Reported confidence with LTBI management [using a Likert scale questionnaire developed by study team]
timeFrame: 3 months
Secondary outcomes:
measure: Proportion of appropriate LTBI care selection
timeFrame: 3 months
measure: Time to LTBI care selection
timeFrame: 3 months
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins
state: Maryland
Study officials:
affiliation: Hopkins University
name: Maunank Shah, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06835465: A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants
Official title: A Phase 1, Open-Label, Single-Dose, Two-Period, Fixed Sequence, Crossover Study to Determine the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Participants
Lead sponsor: Genentech, Inc.
Sponsor class: INDUSTRY
First posted: 2025-02-19
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This is a phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of rifampin on the pharmacokinetics (PK) and safety of divarasib in healthy participants.


Eligibility criteria: Inclusion Criteria:

* Males or females of non-childbearing potential
* Within body mass index (BMI) range of 18.0 to 32.0 kg/m2, inclusive

Exclusion Criteria:

* Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder
* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator
* Poor peripheral venous access

Primary outcomes:
measure: Maximum Plasma Concentration (Cmax) of Divarasib
timeFrame: Day 1 of Period 1 and Day 8 of Period 2
measure: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Divarasib
timeFrame: Day 1 of Period 1 and Day 8 of Period 2
measure: Area Under the Concentration-time Curve from Hour 0 to the Last Measurable Concentration (AUC0-t) of Divarasib
timeFrame: Day 1 of Period 1 and Day 8 of Period 2
Secondary outcomes:
measure: Percentage of Participants With Adverse Events (AEs)
timeFrame: Up to Week 14
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Fortrea Dallas CRU
state: Texas
Study officials:
affiliation: Genentech, Inc.
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT01762865: Acute Bronchitis in Korea:Associated Microorganisms and Clnincal Findings.
Official title: Acute Bronchitis in Korea:Associated Microorganisms and Clnincal Findings.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Bronchitis
Keywords: acute bronchitis, bacteria, virus, clinical symoptoms
Lead sponsor: Hallym University Medical Center
Sponsor class: OTHER
First posted: 2013-01-08
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adult patinets who visit hospitals for recent sputum and/or cough

Brief summary: The investigators hypothesized that acute bronchitis will be associated with various bacteria and viruses.

Detailed description: The investigators will investigate various bacteria and viruses from colleced specimens from patients with acute bronchitis, and also investigate an assoication of the miroorganims with clinical findings

Eligibility criteria: Inclusion Criteria:

* Adults patients aged over 18 years.
* Patients who complain of recent sputum and cough.

Exclusion Criteria:

* Patinets who took antibiotics within 7 days.
* Patinets whose symptoms last for \< 5 days.
* Patients who have definite cause of acute cough such as pneumonia, allergic rhinnits, sinusitis, GERD and drug.
* Immunocompromised patients.

Primary outcomes:
measure: Microorganisms (bacteria and/or viruses) related to acute bronchitis
timeFrame: Outcome measure is just type of microoganisms from collected specimens at hospital visit
Secondary outcomes:
Other outcomes:
Locations:
city: Anyang
country: Korea, Republic of
facility: Pumonary, Allegry and Critical Care Medicine; Hallym University Sacred Heart Hospital
state: Gyeonggi-do
city: Chunchon
country: Korea, Republic of
facility: Chunchon Sacred Heart Hospital
state: Kangwon-do
city: Seoul
country: Korea, Republic of
facility: Kandong Sacred Heart Hospital
Study officials:
affiliation: Pulmonary, Allgery and Critical Care Medicine; Hallym University Sacred Heart Hospital
name: Ki-Suck Jung, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00235365: Metacognitive Therapy for Comorbid Insomnia
Official title: Metacognitive Therapy for Patients With a Psychiatric Disorder and Comorbid Insomnia.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Secondary Insomnia
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
First posted: 2005-10-10
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of meta-cognitive therapy for insomnia.

Detailed description: This study is a randomized controlled trial with 50 patients with a psychiatric disorder and insomnia. The patients will be randomized into two groups of 25 patients. The first group receives meta-cognitive therapy, whereas the second group will be assigned to a waiting list control.

Eligibility criteria: Inclusion Criteria:

* Insomnia secondary to a primary psychiatric disorder

Exclusion Criteria:

* substance abuse, psychotic symptoms, suicidal intentions, severe organic disorder or psychiatric disorder where sleep restriction is not advised, organic sleep disorder.

Primary outcomes:
measure: Scores on rating scales for sleep quality
timeFrame: one year
Secondary outcomes:
measure: Scores on rating scales for depression, psychiatric symptom severity, and cognitive processing.
timeFrame: one year
Other outcomes:
Locations:
Study officials:
affiliation: Norwegian University of Science and Technology
name: Gunnar Morken, PhD MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05036265: Prognostic Factors and Oncological Outcomes in Laparoscopic Liver Resection for CRLM
Official title: Laparoscopic Liver Resection for Colorectal Liver Metastases: Retrospective Analysis of Prognostic Factors and Oncological Outcomes in a Single-center Cohort
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Cancer
Liver Metastases
Surgery
Keywords: hepatopancreatobiliary
laparoscopic liver resection
colorectal liver metastasis
Lead sponsor: General Hospital Groeninge
Sponsor class: OTHER
First posted: 2021-09-05
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who received laparoscopic liver resection for colorectal liver metastases at General Hospital Groeninge between September 2011 and mid-March 2020

Brief summary: Laparoscopic liver resection (LLR) has gained acceptance as an effective treatment for colorectal liver metastases (CRLM) in selected patients, providing similar oncologic outcomes compared to open liver resection (OLR). A single-center retrospective analysis of a prospectively maintained database was performed. The primary aim of this study was to determine prognostic factors for the survival outcomes associated with LLR for CRLM.

Detailed description: LLR was defined as pure LLR, including conversions to OLR. In case of missing data, additional details were retrieved from the individual patient file. Data on patient demographics, timing of diagnosis, neoadjuvant chemotherapy (NAC), tumor characteristics (both primary tumor and CRLM), histopathology, molecular characteristics, operative technique (including classification into anatomically major/technically major/minor LR), intra- and postoperative course, adjuvant chemotherapy (AC) as well as oncological outcomes (OS and DFS) were gathered and analyzed. Postoperative complications were graded according to the Clavien-Dindo classification. Complications were classified as major in case of Clavien-Dindo ≥ 3A.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with colorectal liver metastases
* Patients who received laparoscopic liver resection for colorectal liver metastases
* Patients who received the laparoscopic liver resection between September 2011 and mid-March 2020

Exclusion Criteria:

* Patients with contraindication for laparoscopic liver resection
* Refusal to participate in the study

Primary outcomes:
measure: Survival outcomes
timeFrame: 9 years
measure: Prognostic factors
timeFrame: 9 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03636620: TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial
Official title: Clinical Trial of Transcatheter Arterial Chemoembolization Combined With Radiofrequency/Microwave Ablation in Hepatocellular Carcinoma Beyond Milan Criterial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hepatocellular Carcinoma
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2018-08-17
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: TACE vs.TACE+RFA
Primary purpose: TREATMENT

Brief summary: This study was designed to evaluate the effectiveness of radiofrequency /microwave ablation in patients with hepatocellular carcinoma beyond Milan Criteria.

Detailed description: The aim of this study is to included 120 patients with intermediate stage hepatocellular carcinoma beyond Milan criteria .These patients were randomizedly allocated to TACE treatment group or TACE+RFA/MV .The treatment effectiveness, local tumor control and survival outcome between the two groups were compared.

Eligibility criteria: Inclusion Criteria:

* patients diganosed with hepatocellualr carcinoma beyond Milan criteria
* the presence of a single HCC tumor ≤7 cm in diameter, or multi-nodular HCC tumors (n ≤ 5) small than 7 cm in diameter;
* Child-Pugh A or B
* ECOG score 0-1;
* prothrombin time ≤16 s;
* white cell count ≥3,000/mm3, platelet count ≥40 x 109/L;Hb≥8.5 g/d; ALT/AST≤5×ULN;TB≤3mg/dl;alb≥2.8 g/dl ;Scr ≤2mg/dl

Exclusion Criteria:

* expected survival time \< 12 months before random assignment;
* received anticancer surgery or procedure within one month before assignment;
* concomitant use of any other anticancer therapy(except immunotherapy and herbal medicine ) ;
* existence of portal of hepatic vein invation or extrahepatic metastases;existence of active infection ;
* upper gastrointestinal hemorrhage within one month ; .other serious illness or medical condition.

Primary outcomes:
measure: overall survival
timeFrame: up to 46 months
Secondary outcomes:
measure: objective response rate
timeFrame: up to 46 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: liver cancer institute ,Fudan University
Study officials:
affiliation: Fudan University
name: zheng-gang Ren, doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02872220: To Test for Photo Allergy Reaction of Sunscreens
Official title: A Randomized Study to Assess the Potential for Photoallergy of SPF 50 Y65 110, SPF 50 Y51 002 and SPF 15 V27 104 in Human Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Photoallergy
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-08-19
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The primary objective of this tudy was to evaluate the potential of photoallergy of of sun care products Sun Protection Factor (SPF) 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104 application compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.

The secondary objective aims for evaluation of the safety of SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104 combined with ultraviolet (UV) A/B irradiation by monitoring adverse events (AEs) throughout the study.


Eligibility criteria: Inclusion Criteria:

* Men or women, aged 18 to 65 with good general health
* Fitzpatrick skin type I IV
* Females (of childbearing potential) on acceptable measure of contraception
* Willing to follow study rules, which include: no sun exposure (for example, no swimming, sunbathing, or tanning beds), avoidance of activities that would cause excessive sweating, no use of lotions, creams, or oils on the back area
* Willing to not change the current brand of personal care products such as soaps, body washes, laundry detergent, body sprays, body spritzes, etc. while participating in the study

Primary outcomes:
measure: Evaluation of inflammatory responses
timeFrame: up to 3 weeks
measure: Evaluation of superficial effects
timeFrame: up to 3 weeks
Secondary outcomes:
measure: Adverse event collection as a measure of safety and tolerability
timeFrame: up to 3 weeks
Other outcomes:
Locations:
city: Pinellas Park
country: United States
state: Florida
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT04337320: Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study
Official title: Maternal And Neonatal Outcome of Pregnant Patients With COVID-19
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Maternal-Fetal Relations
Lead sponsor: Kanuni Sultan Suleyman Training and Research Hospital
Sponsor class: OTHER
Collaborators: name: Seda Yilmaz Semerci
First posted: 2020-04-07
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers

Brief summary: Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers


Eligibility criteria: Inclusion Criteria:

* from covid 19 positive mothers
* newborn mothers had not other condition or illness

Exclusion Criteria:

* from covid 19 negative mothers
* childs

Primary outcomes:
measure: Evaluation of apgar status of newborns from covid 19 positive mothers
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Pinar Yalcin Bahat
state: İ̇stanbul
Study officials:
References:
Clinical trial NCT04022720: Platelet-Rich Fibrin in Intraoral Soft Tissue Regeneration
Official title: Role of Platelet-Rich Fibrin in Intraoral Soft Tissue Regeneration of Head and Neck Surgery Patients: A Prospective Clinical Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Mucosal Ulceration
Keywords: platelet rich fibrin (PRF)
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2019-07-17
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Determine if the use of platelet rich fibrin (PRF) improves the rate and quality of healing for intraoral mucosal and epithelial soft tissue defects.


Eligibility criteria: Inclusion Criteria:

* Three categories of patients will be included in this study:

  1. Osteoradionecrosis (ORN) or medication related osteonecrosis of the jaw (MRONJ) patients who present to clinic with exposed bone and no clinical sign of infection.
  2. Patients having an excisional biopsy in clinic performed under local anesthesia resulting in a defect that cannot be easily repaired without compromising normal anatomy or function. These situations include excisions which would result in primary closure under tension or with distorted anatomy, require a local flap, or require healing by secondary intention.
  3. Patients presenting to the post-operative clinic with intraoral surgical wound dehiscence or an intraoral surgical wound healing by secondary intention.

     Exclusion Criteria:
* Patients under 18 years of age.
* Patient's unable to participate in blood draw either due to medical compromise, inability to tolerate the procedure, or inability of the physician to successfully draw the blood at the time of appointment.

Primary outcomes:
measure: Change in rate of healing in intraoral mucosa and epithelium soft tissues
timeFrame: 3 months post-operatively
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Florida
name: Salam Salman, MD, DDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01652820: Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer
Official title: Randomized Phase II Trial Using Concomitant Chemoradiation Plus Induction or Consolidation Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non Small-cell Lung Cancer
Keywords: LUNG
DOCETAXEL
GEMCITABINE
CARBOPLATIN
RADIOTHERAPY
Lead sponsor: Spanish Lung Cancer Group
Sponsor class: OTHER
Collaborators: name: Aventis Pharmaceuticals
First posted: 2012-07-30
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized study in 2 arms, without any masking in patients with non small cell lung cancer, histologically or cytologically confirmed, not liable to surgery, stage IIIB or IIIA, according to the TNM classification of the American Joint Committee for cancer. In one arm will be administered concomitant radiotherapy and carboplatin-docetaxel-gemcitabine followed by docetaxel and, in the other arm will be administered docetaxel-gemcitabine followed by concurrent radiotherapy with carboplatin-docetaxel


Eligibility criteria: Inclusion Criteria:

* Unresectable stage IIIA or B NSCLC patients
* WHO PS 0 or 1
* Weight loss \< 5 % within the last 3 months
* At least one measurable lesion
* Planning CT scan previous to randomization
* Written informed consent

Exclusion Criteria:

* Malignant effusion, supraclavicular node or SVCS
* PTV \> 2000 cm3
* V20 \> 35%
* FEV1 and DLCO both \< 30% or 1 liter at study entry

Primary outcomes:
measure: Overall response rate
timeFrame: From enrollment to first response assesment
Secondary outcomes:
measure: Local control rate at 1 year
timeFrame: 1 year
measure: Time to progression
timeFrame: From enrollment to first progression date
measure: Overall Survival
timeFrame: From enrollment to last follow up or death
Other outcomes:
Locations:
Study officials:
affiliation: Hospital Ramon y Cajal (Madrid)
name: Pilar Garrido, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Germans Trias i Pujol Hospital
name: Rafael Rosell, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Garrido P, Rosell R, Arellano A, Andreu F, Domine M, Perez-Casas A, Cardenal F, Arnaiz Mdel M, Moran T, Morera R, Isla D, Valencia J, Cobo M, Delgado R, Garcia-Gomez R, Calvo F, Zamora J, Ramos A, Massuti B. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study. Lung Cancer. 2013 Jul;81(1):84-90. doi: 10.1016/j.lungcan.2013.03.009. Epub 2013 Apr 21.
Clinical trial NCT04012320: Efficacy and Safety on the Use of Bisphosphonates in Paediatrics
Official title: Efficacy and Safety on the Use of Bisphosphonates in Paediatrics
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bone Fragile
Bisphosphonate-Associated Osteonecrosis
Children
Adverse Events
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2019-07-09
Enrollment: 99
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients under 18 years old who started intravenous bisphosphonates for primary or secondary osteoporosis in paediatric departments of Montpellier and Nimes University Hospitals between January 2012 and August 2018 were included.

Brief summary: The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.


Eligibility criteria: Inclusion Criteria:

* be under 18 years of age
* have been treated by intravenous bisphosphonates for primary or secondary osteoporosis

Exclusion Criteria:

* be over 18 years of age

Primary outcomes:
measure: fracture rates
timeFrame: 2 years
measure: bone mineral density
timeFrame: 2 years
measure: pain frequency
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Nîmes
country: France
facility: CHUNimes
Study officials:
References: